Supernus Pharmaceuticals | SUPN - Debt


Supernus Pharmaceuticals reported $40.9M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Abbott USD 34.05B 20.19B Mar/2026
ANI Pharmaceuticals USD 617.04M 3.28M Dec/2025
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Canopy Growth CAD 278.71M 19.38M Mar/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Pfizer USD 63.73B 231M Mar/2026
Supernus Pharmaceuticals USD 40.9M 74K Mar/2026
United Therapeutics USD 200M 100M Mar/2025
Xeris Pharmaceuticals USD 258.55M 899K Mar/2026